These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12464116)

  • 21. Neuroprotection and dopamine agonists.
    Schapira AH
    Neurology; 2002 Feb; 58(4 Suppl 1):S9-18. PubMed ID: 11909981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacology of dopamine agonists.
    Lam YW
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):17S-25S. PubMed ID: 10641988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine agonists.
    Factor SA
    Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical strategies to prevent and delay motor complications.
    Barone P
    Neurology; 2003 Sep; 61(6 Suppl 3):S12-6. PubMed ID: 14504375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
    Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP
    Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do dopamine agonists provide neuroprotection?
    Yamamoto M
    Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease.
    de Yebenes JG
    Eur J Neurol; 2000 May; 7 Suppl 1():1-2. PubMed ID: 11054151
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dopaminergic neuroprotection and reconstruction of neural network tiara].
    Kitamura Y
    Yakugaku Zasshi; 2010 Oct; 130(10):1263-72. PubMed ID: 20930477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
    J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.